Publications by authors named "Emily E Sutton"
Osteoporosis is a major public health care concern. Although often described as a disease affecting postmenopausal women, researchers and clinicians have emphasized its prevalence in men in recent years. The National Osteoporosis Foundation has stated that up to 25% of men over the age of 50 years will experience a fracture due to osteoporosis.
View Article and Find Full Text PDFDenosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
Ann Pharmacother
December 2012
Article Synopsis
- Denosumab has proven to be an effective and safe treatment for postmenopausal osteoporosis, supported by numerous clinical trials showing improved bone mineral density and reduced fracture risk.
- The review excluded studies focusing on male patients or other conditions, focusing solely on denosumab’s role in postmenopausal women.
- Cost-effectiveness analyses suggest denosumab is a preferable option compared to other treatments like risedronate for women unable or unwilling to use bisphosphonates.